Wyndham Wilson, MD, PhD from the National Cancer Institute, Bethesda, MD talks about drugs that have been developed to indirectly target BCR, such as venetoclax (ABT-199), a Bcl-2 inhibitor; drugs targeting transcription factors, called bromodomain inhibitors, targeting MYC and NF-kappaB.